New immune therapy and stem cell transplant for acute lymphoblastic leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests adding new immunotherapy drugs and possibly a stem cell transplant to the first treatment for adults with acute lymphoblastic leukemia (ALL). The goal is to see if these approaches help people live longer without the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been newly diagnosed with ALL or T-lymphoblastic lymphoma.
- You have not received chemotherapy or targeted antibody treatments before (except steroids or spinal fluid treatments).
- You are in good enough health to walk and take care of yourself (ECOG score 0-2).
- You are willing to use effective birth control during the study and for 6 months after.
- You have health insurance (for French patients) and agree to follow the study schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan for adults aged 18 to 65 who have just been diagnosed with a type of acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome (Ph-negative). The goal is to see how well this therapy works and how safe it is.
This trial tests whether adding targeted drugs to standard chemotherapy works better for adults newly diagnosed with T-ALL. If you have not had any prior treatment for leukemia, this study might be an option.
This trial tests a combination of immunotherapy (using the immune system to fight cancer) and chemotherapy in adults aged 15–65 with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL), a blood cancer. The goal is to see if this combination helps patients achieve remission and survive longer.
This trial tests a combination of low-intensity chemotherapy and a short course of blinatumomab (a targeted immunotherapy) in adults with a certain type of acute leukemia. The goal is to see if this approach helps prepare patients for a stem cell transplant with fewer side effects.
This study tests a combination of chemotherapy, targeted pills (imatinib or ponatinib), and a targeted immunotherapy (blinatumomab) before a stem cell transplant for adults with a specific type of leukemia called Philadelphia chromosome-positive ALL. The goal is to find the best treatment approach.
This Phase 2 study tests how well blinatumomab works for children and adults whose acute lymphoblastic leukemia (ALL) has come back. It also looks at whether results differ based on the patient’s relapse “risk group.”
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.